JP2014515740A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515740A5
JP2014515740A5 JP2014501575A JP2014501575A JP2014515740A5 JP 2014515740 A5 JP2014515740 A5 JP 2014515740A5 JP 2014501575 A JP2014501575 A JP 2014501575A JP 2014501575 A JP2014501575 A JP 2014501575A JP 2014515740 A5 JP2014515740 A5 JP 2014515740A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable domain
antibody molecule
dabigatran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014501575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515740A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/055397 external-priority patent/WO2012130834A1/en
Publication of JP2014515740A publication Critical patent/JP2014515740A/ja
Publication of JP2014515740A5 publication Critical patent/JP2014515740A5/ja
Ceased legal-status Critical Current

Links

JP2014501575A 2011-03-30 2012-03-27 抗凝固薬の解毒剤 Ceased JP2014515740A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161469207P 2011-03-30 2011-03-30
US61/469,207 2011-03-30
PCT/EP2012/055397 WO2012130834A1 (en) 2011-03-30 2012-03-27 Anticoagulant antidotes

Publications (2)

Publication Number Publication Date
JP2014515740A JP2014515740A (ja) 2014-07-03
JP2014515740A5 true JP2014515740A5 (https=) 2015-05-14

Family

ID=45876804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014501575A Ceased JP2014515740A (ja) 2011-03-30 2012-03-27 抗凝固薬の解毒剤

Country Status (23)

Country Link
US (2) US8821871B2 (https=)
EP (1) EP2691156A1 (https=)
JP (1) JP2014515740A (https=)
KR (1) KR20140009437A (https=)
CN (1) CN103476459A (https=)
AP (1) AP2013007046A0 (https=)
AR (1) AR085758A1 (https=)
BR (1) BR112013025031A2 (https=)
CA (1) CA2827787A1 (https=)
CL (1) CL2013002551A1 (https=)
CO (1) CO6771448A2 (https=)
EA (1) EA201301090A1 (https=)
EC (1) ECSP13012997A (https=)
IL (1) IL227653A0 (https=)
MA (1) MA34978B1 (https=)
MX (1) MX2013011092A (https=)
PE (1) PE20140964A1 (https=)
PH (1) PH12013501924A1 (https=)
SG (1) SG193552A1 (https=)
TN (1) TN2013000388A1 (https=)
TW (1) TW201302796A (https=)
UY (1) UY33994A (https=)
WO (1) WO2012130834A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
DK2785700T3 (en) 2011-11-29 2016-06-13 Perosphere Inc Agent for preventing the action of anti-coagulants.
SG11201509982UA (https=) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
KR102322425B1 (ko) * 2013-07-30 2021-11-05 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체
KR101523503B1 (ko) * 2013-09-17 2015-05-29 강원대학교산학협력단 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
WO2015059159A1 (en) 2013-10-25 2015-04-30 Boehringer Ingelheim International Gmbh Anticoagulant antidotes
EP2980218A1 (en) * 2014-07-30 2016-02-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
US20210228742A1 (en) * 2018-04-27 2021-07-29 Seattle Children's Hospital D/B/A Seattle Children's Research Institute In vivo gene therapy using intraosseous delivery of a lentiviralgene construct

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
HU215180B (hu) 1992-01-23 1998-10-28 Merck Patent Gmbh. Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
EP0981548A4 (en) 1997-04-30 2005-11-23 Enzon Inc GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002241922B2 (en) 2001-01-17 2007-10-25 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN1845938B (zh) 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
KR102069498B1 (ko) 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Xa 저해제에 대한 안티도트 및 그것을 사용하는 방법
JP2013502449A (ja) * 2009-08-24 2013-01-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランエテキシレート過剰投与による活性炭の緊急処置
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante

Similar Documents

Publication Publication Date Title
JP2014515740A5 (https=)
JP2014523401A5 (https=)
JP2016516400A5 (https=)
ME02602B (me) Antikoagulantni protivotrovi
JP2015503909A5 (https=)
JP7271430B2 (ja) 抗xi因子抗体
RU2014148502A (ru) Человеческие антитела к fel d1 и способы их применения
JP2016509585A5 (https=)
JP2017538671A5 (https=)
RU2018125515A (ru) Антитело против c5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2017507652A5 (https=)
JP2013529183A5 (https=)
JP2012019790A5 (https=)
JP2014511179A5 (https=)
RU2017107773A (ru) Антитела, специфичные к ммр9
RU2017134909A (ru) Новая форма IL33, мутировавшие формы IL33, антитела, анализы и способы их применения
US20190135903A1 (en) Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
RU2021129189A (ru) Антитела против фактора свертывания xi
JP2016524592A5 (https=)
JP2015508063A5 (https=)
JP2012521218A5 (https=)
TW202318436A (zh) 用於預測細胞激素釋放症候群之多變量模型
JP2014523920A5 (https=)
JP2017501137A5 (https=)
JP2017521054A5 (https=)